fls.txt



item1.txt
According to policy, in addition to normal amortization, these assets are tested for impairment as needed.
We adopted ASC Topic 606, effective September 1, 2018, utilizing the modified retrospective method.
Intangible assets are amortized over their estimated useful lives using the straight-line method, which approximates the pattern in which the majority of the economic benefits are expected to be consumed.
As of May 31, 2019, and August 31, 2018, the Company has a liability for contingent consideration related to its acquisition of the DILIsym Services, Inc.
Goodwill represents the excess of the cost of an acquired entity over the fair value of the acquired net assets.
In September 2017 DILIsym service signed a three-year lease for approximately 1,900 rentable square feet of space in Research Triangle Park, North Carolina.
We maintain a 401(K) Plan for all eligible employees, and we make matching contributions equal to 100% of the employee’s elective deferral, not to exceed 4% of total employee compensation.
On February 28, 2012, we bought out a royalty agreement with Enslein Research of Rochester, New York.
Accumulated amortization as of May 31, 2019 was $3,750.
Rent expense, including common area maintenance fees for the three months ended May 31, 2019, and 2018 was $147,581 and $144,589, respectively, and $436,357 and $424,077 for the nine months ended May 31, 2019 and 2018, respectively.
Most of our contracts are of a duration of one year or less, few, if any of the longer-term contracts have commissions associated with them.
The Company designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students, and it provides consulting services to the pharmaceutical and chemical industries.
Furthermore, in February 2005, the shareholders approved an additional 1,000,000 shares, resulting in the total number of shares that may be granted under the Option Plan to 6,000,000.
During the three and nine-month periods ended May 31, 2019, the Company issued 2,176 and 6,906 shares of stock to non-management directors of the Company valued at $49,025 and $142,888, respectively as compensation for services rendered to the Company.


item2.txt
Consolidated software and software-related sales increased $230,000 or 4.1%, while consolidated consulting and analytical study revenues increased $1.15 million or 39.0% over 3QFY18.
Additional functionality was further requested by the FDA, and a new funded contract was awarded for the 2018-19 period.
If the number is too high (greater than 7), the molecule is not likely to be successful as a drug.
Although the state of the art of this type of software does not enable identifying the best molecule in a series, it does allow early screening of molecules that are highly likely to fail as potential drug candidates (i.e., the worst molecules, which is typically the majority of a virtual chemical library) before synthesizing and testing them.
With continued feedback from KIWI license holders, various visualizations within KIWI 4.0 and the pharmacometric-specific Data Repository continue to be updated with new features and functionality.
The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995.
Consolidated gross margin increased $2.10 million or 12.3%, to $19.21 million in 9moFY19 from $17.10 million in 9moFY18.
When used with a license for ADMET Predictor, MedChem Designer becomes a de novo molecule design tool.
We believe our investment to participate in this initiative enabled us to benefit from, and to contribute to, advancing the prediction of human oral bioavailability from preclinical data, and ensured that we are well-known to member pharmaceutical companies and regulatory agencies.
The initial development is being funded via an NIH small business grant.
In addition, new automated diagnostics are now performed for every NONMEM run, visually reported in the Summarize module.
In addition to full feature releases, going forward regular mini feature releases of KIWI will be distributed to KIWI clients.
Major pharmaceutical companies conduct drug discovery and development efforts through their internal development staffs and through outsourcing.
With continued feedback from KIWI license holders, various visualizations within KIWI 4.0 and the pharmacometric-specific Data Repository continue to be updated with new features and functionality.


item3.txt
The value of these receivables are subject to changes because the receivables may become worth more or less due to changes in currency exchange rates.


item4.txt



part2.txt
  Item 5.


